Skip to main content

Table 1 Characteristics of patients

From: Limited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer

  Total N = 279
Number of patients (%)
Age at diagnosis, median (range years) 55 (25 – 95)
Duration of tamoxifen treatment, median (range months) 21.5 (1 – 70)
Tamoxifen therapy  
 neoadjuvant 7 (2.5)
 adjuvant 258 (92.5)
 metastasis 14 (5)
Breast cancer treatment  
 surgery 276 (98.9)
 received radiation 148 (53)
 received chemotherapy 232 (83.2)
Hormonal status at diagnosis  
 premenopausal 81 (29)
 postmenopausal 115 (41.2)
 unknown 83 (29.7)
Tumor size  
 T1 105 (37.6)
 T2 142 (50.9)
 T3 20 (7.2)
 T4 10 (3.6)
 unknown 2 (0.7)
Node status  
 N 0 132 (47.3)
 N 1 112 (40.3)
 N 2 - 3 30 (10.8)
 unknown 5 (1.8)
Differential grade  
 G1 39 (14)
 G2 129 (46.2)
 G3 67 (24)
 unknown 44 (15.8)
Histology  
 ductal 205 (73.5)
 lobular 30 (10.8)
 other 38 (13.6)
 unknown 6 (2.2)
Hormone receptor status  
 Estrogen+ 269 (96.4)
 Progesterone+ 238 (85.3)
 Both 230 (82.4)
HER2 status  
 positive 64 (22.9)
 negative 210 (75.3)
 unknown 5 (1.8)
  1. Tumor characteristics were at diagnosis. HER2: human epidermal growth factor receptor 2